University of Texas Health Science Center, Cancer Therapy and Research Center, STRF Adult Cancer Program MC 8252, 8403 Floyd Curl Drive, San Antonio, TX 78229-3904, United States.
Drug Resist Updat. 2012 Feb-Apr;15(1-2):106-13. doi: 10.1016/j.drup.2012.03.003. Epub 2012 Apr 5.
Multidrug resistance (MDR) renders cancer cells relatively invulnerable to treatment with many standard cytotoxic anti-cancer agents. Cancer immunotherapy could be an important adjunct for other strategies to treat MDR positive cancers, as resistance to immunotherapy generally is unrelated to mechanisms of resistance to cytotoxic agents. Immunotherapy to combat MDR positive tumors could use any of the following strategies: direct immune attack against MDR positive cells, using MDR as an immune target to deliver cytotoxic agents, capitalization on other immune properties of MDR positive cells, or conditional immunotoxins expressed under MDR control. Additional insights into the immunogenic potential of some cytotoxic agents can also be brought to bear on these strategies. This review will highlight key concepts in cancer immunotherapy and illustrate immune principles and strategies that have been or could be used to help destroy MDR positive tumor cells, either alone or in rational combinations.
多药耐药性(MDR)使癌细胞相对不易受到许多标准细胞毒性抗癌药物的治疗。癌症免疫疗法可能是治疗 MDR 阳性癌症的其他策略的重要辅助手段,因为对免疫疗法的耐药性通常与对细胞毒性药物的耐药性机制无关。用于对抗 MDR 阳性肿瘤的免疫疗法可以使用以下任何一种策略:直接针对 MDR 阳性细胞进行免疫攻击,将 MDR 用作免疫靶标来递送细胞毒性药物,利用 MDR 阳性细胞的其他免疫特性,或在 MDR 控制下表达条件免疫毒素。还可以将一些细胞毒性药物的免疫原性潜力的更多见解应用于这些策略。本综述将重点介绍癌症免疫疗法的关键概念,并说明已经或可以用于帮助破坏 MDR 阳性肿瘤细胞的免疫原理和策略,无论是单独使用还是合理组合使用。